| Followers | 7 |
| Posts | 5499 |
| Boards Moderated | 0 |
| Alias Born | 09/11/2013 |
Friday, May 01, 2020 12:10:34 PM
I don't think Diwan is in this game to defeat every known virus known to mankind. I think he's in it to take as much money as he can. Sure, he could be fabulously wealthy if NNVC succeeds, but I think he's willing to settle on being very wealthy if it doesn't.
I truly believe, if he thought his own mystical science worked, he'd be plunking every single penny into keeping NNVC afloat. But I think his efficient Theracour 30% money laundering machine, his pretty decent salary, his stock options and his bonuses (yes, bonuses for accomplishing NOTHING!), is indicative, at least to me, that he's taken more of a "take the money and run" mindset.
I think the science, even if it is valid, upon which as a non-scientist I can't really render an opinion, is a moot point.
I truly believe, if he thought his own mystical science worked, he'd be plunking every single penny into keeping NNVC afloat. But I think his efficient Theracour 30% money laundering machine, his pretty decent salary, his stock options and his bonuses (yes, bonuses for accomplishing NOTHING!), is indicative, at least to me, that he's taken more of a "take the money and run" mindset.
I think the science, even if it is valid, upon which as a non-scientist I can't really render an opinion, is a moot point.
Just because you can doesn't mean you should.
Recent NNVC News
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
